ClinicalTrials.gg
Active, not recruitingNCT05556512SURMOUNT-MMOUpdated Nov 12, 2026

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity and Overweight, sponsored by Eli Lilly and Company. Active, not recruiting at 672 sites in 28 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Updated Nov 12, 20263 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
15,374
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
Largest of 104
15,374 · median 69
Started
2022
with 1 other
Phase 3
26 of 104
7 open now
Primary completion
2027-10
later than 40 of 78 live
Registered
14th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one has the largest enrollment, is one of 2 that started in 2022, is one of 26 in phase 3, reaches primary completion later than 40 of the 78 other live ones, and was the 14th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.

03

Conditions studied

  • Obesity
  • Overweight
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) ≥27.0 kilogram/square meter (kg/m ²)
  • Are either

    • individuals ≥40 years of age with established cardiovascular disease (CVD).

      • CVD is defined as meeting at least one of the following:

        • Coronary artery disease
        • Cerebrovascular disease
      • Peripheral arterial disease OR
      • individuals without established CVD but have the presence of cardiovascular (CV) risk factors (primary prevention)
      • women 55-69 years of age or men 50-64 years of age with at least 3 risk factors like tobacco use, dyslipidemia, hypertension at screening, or

        • women ≥70 years of age or men, ≥65 years of age with at least 2 risk factors at screening.

Exclusion criteria

Exclusion Criteria:

  • Have type 1 diabetes (T1D) or (T2D), history of ketoacidosis, or hyperosmolar state/coma
  • Have laboratory evidence diagnostic of diabetes mellitus at screening of ≥6.5% (≥48 millimole/mole (mmol/mol) or fasting glucose (FG) ≥126 milligram/deciliter (≥7.0 millimole/liter (mmol/L).
  • Any one of the following CV conditions within 90 days prior to screening

    • MI
    • acute coronary syndrome
    • stroke
    • coronary or peripheral arterial revascularization procedure, which may also include carotid artery revascularization, or
    • acute decompensated heart failure
  • Have a known gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction or have undergone or currently planning any gastric bypass (metabolic) surgery or restrictive bariatric surgery. Note: Liposuction or abdominoplasty are not considered as gastric bypass procedures.
  • Have a history of chronic or acute pancreatitis
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
  • Have acute or chronic hepatitis, or clinical signs or symptoms of any other liver disease, or have elevated liver enzyme measurements, determined by the central laboratory at screening
  • Have a presence or history of malignant neoplasms within the past 5 years prior to screening.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
15,374 participants (actual)

Study arms

  • Experimental
    Tirzepatide

    Participants will receive escalated doses of tirzepatide subcutaneously (SC) up to a maximum tolerated dose.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants will receive tirzepatide matched placebo.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Time to First Occurrence of Any Component Event of Composite (All-Cause Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Coronary Revascularization, or Heart Failure Events)

    Time to first occurrence of any component event of composite, all-cause death, nonfatal MI, nonfatal stroke, coronary revascularization, or heart failure events that results in hospitalization or urgent visits.

    Time frame: Up to 5 Years

Secondary outcomes

  1. Time to Onset of Type 2 Diabetes (T2D)

    Time frame: Up to 5 Years

  2. Change from Baseline in Estimated Glomerular Filtration Rate (eGFR)

    In participants with high or very high risk chronic kidney disease

    Time frame: Up to 5 Years

  3. Time to First Occurrence of Any Component Event of Major Adverse Cardiovascular Events-3 (MACE-3) (CV Death, Nonfatal MI or Nonfatal Stroke)

    Time to first occurrence of any component event of MACE-3 (CV death, nonfatal MI or nonfatal stroke)

    Time frame: Up to 5 Years

  4. Mean Change from Baseline Short Form-36 Version 2 (SF-36 v2) Acute Form Physical Functioning Domain Score

    The SF-36 v2 acute, 1-week recall version is a 36-item generic, participant-administered measure designed to assess the following 8 domains (Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role - Emotional, and Mental Health. Each domain is scored individually and further aggregated into 2 health component summary scores, physical component and mental component summary. Scoring of each domain and both summary scores are norm-based and presented in the form of T-scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health.

    Time frame: Baseline, 2 Years

  5. Time to the Occurrence of All-cause Death

    Time frame: Up to 5 Years

  6. Time to First Occurrence of CV Death

    Time frame: Up to 5 Years

  7. Time to First Occurrence of MI

    Time frame: Up to 5 Years

  8. Time to First Occurrence of Stroke

    Time frame: Up to 5 Years

  9. Time to First Occurrence of Coronary Revascularization

    Time frame: Up to 5 Years

  10. Time to First Occurrence Heart Failure (HF) Events

    Time to first occurrence heart failure (HF) events that result in hospitalization or urgent visits

    Time frame: Up to 5 Years

  11. Time to First Occurrence of Hospitalization for Unstable Angina

    Time frame: Up to 5 Years

  12. Time to first occurrence of Hospitalization or Urgent Visit

    Time to first occurrence of hospitalization or urgent visit due to atrial fibrillation, or cardioversion or ablation for atrial fibrillation

    Time frame: Up to 5 Years

  13. Time to First Occurrence of Any Component Event of the Composite Endpoint (eGFR, ESRD, or Renal Death)

    Time to first occurrence of any component event of the composite endpoint ≥40% sustained decline in eGFR, ESRD, or renal death.

    Time frame: Up to 5 Years

  14. Percent Change from Baseline in Body Weight

    Time frame: Baseline, 156 Weeks

  15. Change from Baseline in Systolic Blood Pressure (SBP) in Millimeter Mercury (mmHg)

    Time frame: Baseline, 156 Weeks

  16. Change from Baseline Diastolic Blood Pressure (DBP) (mmHg)

    Time frame: Baseline, 156 Weeks

  17. Percentage of Participants with Hemoglobin A1c (HbA1c) <39 Millimole/Mole (mmol/mol) (5.7%)

    Percentage of participants with HbA1c \<39 mmol/mol (5.7%) at each time where HbA1c is assessed for participants with a screening HbA1c ≥39 mmol/mol.

    Time frame: Up to 5 Years

  18. Time to First Occurrence of Any Component Event of Composite Endpoint (All-Cause Death, Nonfatal MI, Nonfatal Stroke, Coronary Revascularization, Heart Failure Events, > 40% Sustained Decline in eGFR, or End Stage Renal Disease)

    In participants with prediabetes

    Time frame: Up to 5 Years

07

Study locations

672 sites

Showing the first 100 of 672 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Antza C, Anyfanti P, Poutachidis A, Poulis D, Belancic A, Kotsis V. Hypertension in young adults with obesity: new mechanisms and therapeutic options. Pol Arch Intern Med. 2026 Feb 26;136(2):17203. doi: 10.20452/pamw.17203. Epub 2026 Jan 23. PubMed 41589430 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2022 (actual). Primary completion is estimated for Oct 2027, 60 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 60 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2022
First posted
Sep 27, 2022
StartActual
Oct 11, 2022
Primary completionEst.
Oct 2027
CompletionEst.
Oct 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed
Show 3 added (1 Australia, 1 Israel, 1 Romania)
  • Paratus Clinical Research Canberra · Deakin, Australia
  • Yitzhak Shamir Medical Center · Tsrifin, Israel
  • Futuremeds - Brașov · Brasov, Romania
Show 2 removed
  • Paratus Clinical Research Canberra · Bruce, Australia
  • Yitzhak Shamir Medical Center · Ẕerifin, Israel
across 2 updates, Oct 7, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    2 sites added, 1 site removed
    Show 2 added (1 Israel, 1 Romania)
    • Yitzhak Shamir Medical Center · Tsrifin, Israel
    • Futuremeds - Brașov · Brasov, Romania
    Show 1 removed
    • Yitzhak Shamir Medical Center · Ẕerifin, Israel
    + 1 other change: verification date
  2. Oct 7, 2026
    1 site added, 1 site removed
    Show site
    • Paratus Clinical Research Canberra · Deakin, Australia
    Show 1 removed
    • Paratus Clinical Research Canberra · Bruce, Australia
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05556512
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Oct 11, 2022
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559 or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion